Literature DB >> 25301936

Enhanced methamphetamine metabolism in rhesus macaque as compared with human: an analysis using a novel method of liquid chromatography with tandem mass spectrometry, kinetic study, and substrate docking.

Ravinder Earla1, Santosh Kumar1, Lei Wang2, Steven Bosinger2, Junhao Li2, Ankit Shah2, Mohitkumar Gangwani2, Anantha Nookala2, Xun Liu2, Lu Cao2, Austin Jackson2, Peter S Silverstein2, Howard S Fox2, Weihua Li2, Anil Kumar2.   

Abstract

Methamphetamine (MA), which remains one of the widely used drugs of abuse, is metabolized by the cytochrome P450 (P450) family of enzymes in humans. However, metabolism of methamphetamine in macaques is poorly understood. Therefore, we first developed and validated a very sensitive liquid chromatography with tandem mass spectrometry (LC-MS/MS) method using solid phase extraction of rhesus plasma with a lower limit of quantitation at 1.09 ng/ml for MA and its metabolites, 4-hydroxy methamphetamine (4-OH MA), amphetamine (AM), 4-OH amphetamine (4-OH AM), and norephedrine. We then analyzed plasma samples of MA-treated rhesus, which showed >10-fold higher concentrations of AM (∼29 ng/ml) and 4-OH AM (∼28 ng/ml) than MA (∼2 ng/ml). Because the plasma levels of MA metabolites in rhesus were much higher than in human samples, we examined MA metabolism in human and rhesus microsomes. Interestingly, the results showed that AM and 4-OH AM were formed more rapidly and that the catalytic efficiency (Vmax/Km) for the formation of AM was ∼8-fold higher in rhesus than in human microsomes. We further examined the differences in these kinetic characteristics using three selective inhibitors of each human CYP2D6 and CYP3A4 enzymes. The results showed that each of these inhibitors inhibited both d- and l-MA metabolism by 20%-60% in human microsomes but not in rhesus microsomes. The differences between human and rhesus CYP2D6 and CYP3A4 enzymes were further assessed by docking studies for both d and l-MA. In conclusion, our results demonstrated an enhanced MA metabolism in rhesus compared with humans, which is likely to be caused by differences in MA-metabolizing P450 enzymes between these species.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25301936      PMCID: PMC4244873          DOI: 10.1124/dmd.114.059378

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  53 in total

1.  Short communication: quantitative proteomic plasma profiling reveals activation of host defense to oxidative stress in chronic SIV and methamphetamine comorbidity.

Authors:  Gurudutt Pendyala; Sunia A Trauger; Gary Siuzdak; Howard S Fox
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-07       Impact factor: 2.205

2.  Fast and highly selective LC-MS/MS screening for THC and 16 other abused drugs and metabolites in human hair to monitor patients for drug abuse.

Authors:  Remco A Koster; Jan-Willem C Alffenaar; Ben Greijdanus; Joanneke E L VanDernagel; Donald R A Uges
Journal:  Ther Drug Monit       Date:  2014-04       Impact factor: 3.681

3.  Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.

Authors:  Haruka Nishimuta; Kimihiko Sato; Yasuyuki Mizuki; Masashi Yabuki; Setsuko Komuro
Journal:  Drug Metab Pharmacokinet       Date:  2011-03-04       Impact factor: 3.614

4.  Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection.

Authors:  Howard Hendrickson; Elizabeth Laurenzana; S Michael Owens
Journal:  AAPS J       Date:  2006-11-22       Impact factor: 4.009

5.  Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection.

Authors:  Santosh Kumar; Huan Qiu; Numan Oezguen; Holger Herlyn; James R Halpert; Leszek Wojnowski
Journal:  Drug Metab Dispos       Date:  2009-03-19       Impact factor: 3.922

6.  Simultaneous determination of methamphetamine, 3,4-methylenedioxy-N-methylamphetamine, 3,4-methylenedioxy-N-ethylamphetamine, N,N-dimethylamphetamine, and their metabolites in urine by liquid chromatography-electrospray ionization-tandem mass spectrometry.

Authors:  Jin Young Kim; Jae Chul Cheong; Beom Jun Ko; Sang Kyu Lee; Hye Hyun Yoo; Changbae Jin; Moon Kyo In
Journal:  Arch Pharm Res       Date:  2008-12-20       Impact factor: 4.946

7.  Metabolomic analyses of body fluids after subchronic manganese inhalation in rhesus monkeys.

Authors:  David C Dorman; Melanie F Struve; Amy Norris; Alan J Higgins
Journal:  Toxicol Sci       Date:  2008-08-06       Impact factor: 4.849

8.  Resolution of methamphetamine stereoisomers in urine drug testing: urinary excretion of R(-)-methamphetamine following use of nasal inhalers.

Authors:  R L Fitzgerald; J M Ramos; S C Bogema; A Poklis
Journal:  J Anal Toxicol       Date:  1988 Sep-Oct       Impact factor: 3.367

9.  The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers.

Authors:  Markus R Meyer; Frank T Peters; Hans H Maurer
Journal:  Drug Metab Dispos       Date:  2008-08-25       Impact factor: 3.922

10.  MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?

Authors:  Rafael de la Torre; Samanta Yubero-Lahoz; Ricardo Pardo-Lozano; Magí Farré
Journal:  Front Genet       Date:  2012-11-12       Impact factor: 4.599

View more
  6 in total

1.  Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.

Authors:  Narasimha M Midde; Yuqing Gong; Theodore J Cory; Junhao Li; Bernd Meibohm; Weihua Li; Santosh Kumar
Journal:  Pharm Res       Date:  2017-06-14       Impact factor: 4.200

Review 2.  Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems.

Authors:  Santosh Kumar; P S S Rao; Ravindra Earla; Anil Kumar
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-12-24       Impact factor: 4.481

Review 3.  Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1.

Authors:  P S S Rao; Narasimha M Midde; Duane D Miller; Subhash Chauhan; Anil Kumar; Santosh Kumar
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

Review 4.  Impact of methamphetamine on infection and immunity.

Authors:  Sergio A Salamanca; Edra E Sorrentino; Joshua D Nosanchuk; Luis R Martinez
Journal:  Front Neurosci       Date:  2015-01-12       Impact factor: 4.677

5.  Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.

Authors:  Narasimha M Midde; Mohammad A Rahman; Chetan Rathi; Junhao Li; Bernd Meibohm; Weihua Li; Santosh Kumar
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

6.  Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4.

Authors:  Anantha R Nookala; Junhao Li; Anusha Ande; Lei Wang; Naveen K Vaidya; Weihua Li; Santosh Kumar; Anil Kumar
Journal:  PLoS One       Date:  2016-01-07       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.